Affiliation:
1. Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA
2. Research Services, Central Virginia Veterans Affairs Healthcare System, Richmond, VA 23249, USA
Abstract
The rising prevalence of nonalcoholic fatty liver disease (NAFLD)-related cirrhosis highlights the need for a better understanding of the molecular mechanisms responsible for driving the transition of hepatic steatosis (fatty liver; NAFL) to steatohepatitis (NASH) and fibrosis/cirrhosis. Obesity-related insulin resistance (IR) is a well-known hallmark of early NAFLD progression, yet the mechanism linking aberrant insulin signaling to hepatocyte inflammation has remained unclear. Recently, as a function of more distinctly defining the regulation of mechanistic pathways, hepatocyte toxicity as mediated by hepatic free cholesterol and its metabolites has emerged as fundamental to the subsequent necroinflammation/fibrosis characteristics of NASH. More specifically, aberrant hepatocyte insulin signaling, as found with IR, leads to dysregulation in bile acid biosynthetic pathways with the subsequent intracellular accumulation of mitochondrial CYP27A1-derived cholesterol metabolites, (25R)26-hydroxycholesterol and 3β-Hydroxy-5-cholesten-(25R)26-oic acid, which appear to be responsible for driving hepatocyte toxicity. These findings bring forth a “two-hit” interpretation as to how NAFL progresses to NAFLD: abnormal hepatocyte insulin signaling, as occurs with IR, develops as a “first hit” that sequentially drives the accumulation of toxic CYP27A1-driven cholesterol metabolites as the “second hit”. In the following review, we examine the mechanistic pathway by which mitochondria-derived cholesterol metabolites drive the development of NASH. Insights into mechanistic approaches for effective NASH intervention are provided.
Funder
Virginia Commonwealth University Internal Medicine Pilot Project
U.S. Department of Veterans Affairs
Reference150 articles.
1. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease;Ludwig;Mayo Clin. Proc.,1980
2. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018
3. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis;Riazi;Lancet Gastroenterol. Hepatol.,2022
4. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis;Younossi;Hepatology,2019
5. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study;Armstrong;Lancet,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献